Wedbush analyst David Nierengarten last night initiated coverage of Prime Medicine with an Outperform rating and $12 price target. The shares shares are undervalued based on a positive long-term outlook on the company’s “differentiated and versatile” gene editing platform, prime editing, the analyst tells investors in a research note. The firm says prime editing is capable of repairing 90% of known genetic mutations. It believes prime editing could be the go-to technology to treat or cure a significant number of genetic diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine price target lowered to $20 from $24 at Guggenheim
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine reports FY23 EPS ($2.18), consensus ($1.97)
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
